Article
Oncology
Amy C. Mandigo, Wei Yuan, Kexin Xu, Peter Gallagher, Angel Pang, Yi Fang Guan, Ayesha A. Shafi, Chellappagounder Thangavel, Beshara Sheehan, Denisa Bogdan, Alec Paschalis, Jennifer J. McCann, Talya S. Laufer, Nicolas Gordon, Irina A. Vasilevskaya, Emanuela Dylgjeri, Saswati N. Chand, Matthew J. Schiewer, Josep Domingo-Domenech, Robert B. Den, Jeff Holst, Peter A. McCue, Johann S. de Bono, Christopher McNair, Karen E. Knudsen
Summary: This study identifies the stage-specific consequences of RB loss across cancer progression, which directly impact tumor response to clinically utilized therapeutics. It is the first to investigate the effect of RB loss on global metabolic regulation and link RB/E2F1 to redox control in multiple advanced diseases.
Article
Cell Biology
Jianming Zhang, Jing Zhang, Zhongmao Fu, Yuan Zhang, Zai Luo, Pengshan Zhang, Yitian Xu, Chen Huang
Summary: Accumulating evidence suggests that downregulation of carbohydrate response element binding protein (CHREBP) is associated with gastric cancer (GC) development and progression. CHREBP acts as an independent diagnostic marker of GC and its downregulation promotes cell proliferation and inhibits apoptosis. Furthermore, CHREBP transcriptionally inhibits cyclin D1 expression in GC cells, suggesting its involvement in GC growth and apoptosis through targeting the cyclin D1-Rb-E2F1 pathway.
CELL DEATH DISCOVERY
(2022)
Article
Cell Biology
Xiaoling Xu, Tao Zhang, Meiju Zhang, Lanlan Li, Ge Deng, Zheng Lu, Zhenyu Zhang, Yan Du, Yubin Feng, Xiaowen Feng, Xiaoqing Peng, Feihu Chen
Summary: This study found that ATPR can promote the differentiation of MCL cells and achieve it through regulating the SOX11/CyclinD1/Rb/E2F1 pathway. This provides experimental foundation for developing differentiation therapy for MCL using ATPR.
CELLULAR SIGNALLING
(2022)
Article
Multidisciplinary Sciences
Depeng Wang, Wei Xu, Minghua Huang, Wei Ma, Yulu Liu, Xingchen Zhou, Qingrui Yang, Kun Mu
Summary: Drug resistance is common in triple-negative breast cancer (TNBC) and leads to poor prognosis. Targeting the DNA damage response (DDR) has shown to be effective in overcoming chemotherapy resistance in TNBC. CENPF, a key regulator of cell cycle progression, is highly expressed in TNBC and is associated with chemotherapy resistance. Knockdown of CENPF increases cytotoxicity in TNBC cells and overcomes adriamycin resistance. CENPF targets the Chk1-mediated G2/M phase arrest and competes with E2F1 in TNBC, providing a novel mechanism to overcome chemotherapy resistance.
SCIENTIFIC REPORTS
(2023)
Article
Cell Biology
Namin Duan, Xiaohui Hu, Huiran Qiu, Rui Zhou, Yuru Li, Wenxia Lu, Yamin Zhu, Shuang Shen, Wenhui Wu, Feifei Yang, Ning Liu
Summary: In this study, a novel and efficient HDAC1 inhibitor called HR488B was found to exhibit effective anti-colorectal cancer (CRC) activity. HR488B induced cell cycle arrest and apoptosis in CRC cells by causing mitochondrial dysfunction, reactive oxygen species (ROS) generation, and DNA damage accumulation. Furthermore, HR488B suppressed the growth of CRC cells by decreasing the expression of E2F1 and preventing its release from the E2F1/Rb/HDAC1 complex. Therefore, HR488B may be a potential candidate for CRC therapy and targeting the E2F1/Rb/HDAC1 axis shows promise as a therapeutic approach for CRC.
CELL DEATH & DISEASE
(2023)
Article
Cell Biology
Fengxia Chen, Qingqing Wang, Xiaoyan Yu, Ningning Yang, Yuan Wang, Yangyang Zeng, Zhewen Zheng, Fuxiang Zhou, Yunfeng Zhou
Summary: TNBC is a highly aggressive subtype with poor prognosis and high metastatic potential. Downregulation of MCPIP1 in TNBC is associated with poor survival rates, while its overexpression can suppress cell proliferation by regulating alternative splicing. MCPIP1's role as a tumor suppressor and potential treatment target in TNBC is highlighted in this study.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Jing Xu, Lei Liu, Ranran Ma, Yawen Wang, Xu Chen, Haiting Liu, Youxin Ji, Tiantian Liu, Peng Gao
Summary: This study revealed that elevated KIF26A expression in breast cancer tissues is associated with lymph node metastasis. KIF26A promotes cell proliferation and cell cycle progression in breast cancer cells. The core promotor region of human KIF26A gene is located at position -395 to -385, upstream of the transcription start site. The transcriptional factor E2F1 activates KIF26A expression, leading to cell cycle progression through the CDK-RB-E2Fs pathway.
FRONTIERS IN ONCOLOGY
(2021)
Review
Medicine, Research & Experimental
Zhenzhen Li, Chanjun Sun, Zhihai Qin
Summary: Cancer cells adapt their metabolism to proliferate and survive in harsh environments, with a close relationship between tumor microenvironment and cancer-associated fibroblasts (CAFs) playing key roles in tumor growth and metastasis. CAFs act as major regulators in shaping tumor metabolism, especially through dysregulation of metabolic pathways, influencing cancer cell behavior and response to therapy. The interaction and crosstalk between cancer cells and CAFs contribute to metabolic reprogramming that impacts cancer cell growth and progression.
Article
Multidisciplinary Sciences
Carmen Aguilar, Susana Costa, Claire Maudet, R. P. Vivek-Ananth, Sara Zaldivar-Lopez, Juan J. Garrido, Areejit Samal, Miguel Mano, Ana Eulalio
Summary: Cells infected with Salmonella Typhimurium activate the ER-stress response in both infected and bystander cells, leading to JNK pathway activation, downregulation of transcription factor E2F1, and reprogramming of microRNA expression. This response is specific to Salmonella and is mediated by the host factor HMGB1, contributing to increased infection efficiency in bystander cells.
NATURE COMMUNICATIONS
(2021)
Article
Pharmacology & Pharmacy
Verona Buocikova, Silvia Tyciakova, Eleftherios Pilalis, Chara Mastrokalou, Maria Urbanova, Miroslava Matuskova, Lucia Demkova, Veronika Medova, Eleonora Marta Longhin, Elise Runden-Pran, Maria Dusinska, Ivan Rios-Mondragon, Mihaela Roxana Cimpan, Alena Gabelova, Andrea Soltysova, Bozena Smolkova, Aristotelis Chatziioannou
Summary: DAC, in combination with traditional anticancer drugs, shows promise as a treatment option for solid tumors. Increasing DCK expression to potentiate DAC's effect did not lead to changes in global DNA methylation levels or cell viability.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Jingjing Li, Wen Bi, Fang Lu, Bei Pan, Mengqiu Xiong, Lubanga Nasifu, Zhenlin Nie, Bangshun He
Summary: This study comprehensively evaluated the prognostic value of E2F1 in cancer patients based on published data. The results showed that higher expression of E2F1 is significantly correlated with unfavorable overall survival and disease-free survival. E2F1 could serve as a prognostic biomarker in cancer patients.
Article
Engineering, Civil
Manuel Seet, Jonathan Harvy, Rohit Bose, Andrei Dragomir, Anastasios Bezerianos, Nitish Thakor
Summary: The study found that trust levels significantly decreased in subjects during malfunctions in full automation driving mode of autonomous vehicles, while it remained stable in conditional automation driving mode. EEG analysis revealed enhanced approach motivation and disrupted executive cognition during malfunctions in full automation mode, with no neurocognitive disruptions observed in conditional automation mode malfunctions.
IEEE TRANSACTIONS ON INTELLIGENT TRANSPORTATION SYSTEMS
(2022)
Article
Oncology
Masaki Shiota, Naohiro Fujimoto, Takashi Matsumoto, Shigehiro Tsukahara, Shohei Nagakawa, Shohei Ueda, Miho Ushijima, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Takeshi Uchiumi, Masatoshi Eto
Summary: Genetic variations in TGFB1 were found to be associated with adverse characteristics and progression risk in patients with metastatic prostate cancer undergoing ADT, but not in those with non-metastatic disease, indicating a distinct role of TGF-beta signaling between these two groups of patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Health Care Sciences & Services
Vania Fontani, Sara Cruciani, Sara Santaniello, Salvatore Rinaldi, Margherita Maioli
Summary: Human breast adenocarcinoma has the ability to metastasize to various tissues, and current chemotherapeutic drugs target different mechanisms of cell replication. The use of REAC technology on MCF-7 cells showed potential in inhibiting proliferation and modulating tumor biomarkers. These findings suggest the potential application of REAC RGN in breast cancer treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Medicine, Research & Experimental
Brandon L. McClellan, Santiago Haase, Felipe J. Nunez, Mahmoud S. Alghamri, Ali A. Dabaja, Pedro R. Lowenstein, Maria G. Castro
Summary: Epigenetic remodeling is a key factor in glioma progression, contributing to gliomagenesis, tumor progression, and responses to immunotherapies. This remodeling involves changes in histone modifications, chromatin structure, and DNA methylation driven by mutations in genes such as H3C1, H3F3A, IDH1/2, ATRX, and others. Recent studies have focused on understanding the role of epigenetic alterations in shaping the tumor microenvironment (TME) and how therapies targeting epigenetic dysregulation affect the immune response and outcomes in glioma. The link between epigenetic remodeling and the glioma TME provides insights for the development of epigenetic-targeting therapies to improve antitumor immune response.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Biochemical Research Methods
Dario Romagnoli, Agostina Nardone, Francesca Galardi, Marta Paoli, Francesca De Luca, Chiara Biagioni, Gian Marco Franceschini, Marta Pestrin, Giuseppina Sanna, Erica Moretti, Francesca Demichelis, Ilenia Migliaccio, Laura Biganzoli, Luca Malorni, Matteo Benelli
Summary: DNA-methylation alterations are common in cancer and can be used as ideal markers for tumor quantification and classification. The computational framework MIMESIS utilizes minimal DNA-methylation signatures to accurately estimate tumor content and classify tumor type and molecular subtype in tissue and cell-free DNA samples. The study demonstrates the potential of MIMESIS in developing cost-effective and scalable DNA-methylation assays for precision oncology in clinical practice.
BRIEFINGS IN BIOINFORMATICS
(2023)
Article
Biochemistry & Molecular Biology
Emma Scott, Kirsty Hodgson, Beatriz Calle, Helen Turner, Kathleen Cheung, Abel Bermudez, Fernando Jose Garcia Marques, Hayley Pye, Edward Christopher Yo, Khirul Islam, Htoo Zarni Oo, Urszula L. McClurg, Laura Wilson, Huw Thomas, Fiona M. Frame, Margarita Orozco-Moreno, Kayla Bastian, Hector M. Arredondo, Chloe Roustan, Melissa Anne Gray, Lois Kelly, Aaron Tolson, Ellie Mellor, Gerald Hysenaj, Emily Archer Goode, Rebecca Garnham, Adam Duxfield, Susan Heavey, Urszula Stopka-Farooqui, Aiman Haider, Alex Freeman, Saurabh Singh, Edward W. Johnston, Shonit Punwani, Bridget Knight, Paul McCullagh, John McGrath, Malcolm Crundwell, Lorna Harries, Denisa Bogdan, Daniel Westaby, Gemma Fowler, Penny Flohr, Wei Yuan, Adam Sharp, Johann de Bono, Norman J. Maitland, Simon Wisnovsky, Carolyn R. Bertozzi, Rakesh Heer, Ramon Hurtado Guerrero, Mads Daugaard, Janne Leivo, Hayley Whitaker, Sharon Pitteri, Ning Wang, David J. Elliott, Benjamin Schumann, Jennifer Munkley
Summary: Prostate cancer is the leading cancer among men, causing over 350,000 deaths worldwide annually. This study reveals that the glycosyltransferase enzyme GALNT7 is upregulated in prostate cancer tissue and can be used as a biomarker to diagnose the disease with higher accuracy than the traditional PSA test. Additionally, GALNT7 is found to play a role in promoting prostate tumor growth and is associated with cell cycle and immune signaling pathways. Overall, this study highlights the importance of GALNT7-mediated O-glycosylation in prostate cancer progression.
Article
Oncology
Nicolo Bancaro, Bianca Cali, Martina Troiani, Angela Rita Elia, Rydell Alvarez Arzola, Giuseppe Attanasio, Ping Lai, Mateus Crespo, Bora Gurel, Rita Pereira, Christina Guo, Simone Mosole, Daniela Brina, Mariantonietta D'Ambrosio, Emiliano Pasquini, Clarissa Spataro, Elena Zagato, Andrea Rinaldi, Mattia Pedotti, Simona Di Lascio, Francesco Meani, Monica Montopoli, Matteo Ferrari, Andrea Gallina, Luca Varani, Ricardo Pereira Mestre, Marco Bolis, Silke Gillessen Sommer, Johann de Bono, Arianna Calcinotto, Andrea Alimonti
Summary: Tumor cells promote the recruitment of immunosuppressive neutrophils, a subset of myeloid cells driving immune suppression, tumor proliferation, and treatment resistance. We have identified a subset of neutrophils that have upregulated expression of cellular senescence markers and persist in the tumor microenvironment. These senescent-like neutrophils express TREM2 and are more immunosuppressive and tumor-promoting than canonical immunosuppressive neutrophils.
Article
Oncology
Annalisa Petrelli, Sabrina Rizzolio, Filippo Pietrantonio, Sara E. Bellomo, Matteo Benelli, Loris De Cecco, Dario Romagnoli, Enrico Berrino, Claudia Orru, Salvatore Ribisi, Daniel Moya-Rull, Cristina Migliore, Daniela Conticelli, Irene M. Maina, Elisabetta Puliga, Violeta Serra, Benedetta Pellegrino, Alba Llop-Guevara, Antonino Musolino, Salvatore Siena, Andrea Sartore-Bianchi, Michele Prisciandaro, Federica Morano, Maria Antista, Uberto Fumagalli, Giovanni De Manzoni, Maurizio Degiuli, Gian Luca Baiocchi, Marco F. Amisano, Alessandro Ferrero, Caterina Marchio, Simona Corso, Silvia Giordano
Summary: Although clinical trials on gastric cancer patients have shown negative results, PARP inhibitors (PARPis) still have potential as a therapy for a subpopulation of gastric cancer patients. An estimated 7% to 12% of gastric cancers have mutations associated with HR failure, suggesting possible benefits from PARPis. Preclinical trials using patient-derived xenografts (PDXs) and primary cells showed that olaparib was effective in PDXs with BRCA2 mutations. Additionally, evaluation of HR deficiency and mutational signatures effectively stratified responders and nonresponders.
Article
Oncology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De Santis, Ignacio Duran, Ross Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara A. Jereczek-Fossa, Rob Jones, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel J. Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hiroji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The APCCC 2022 addressed questions in various areas of advanced prostate cancer and provided voting results to supplement guidelines based on level 1 evidence. These results can assist clinicians, patients, research funders, and policy makers in making management decisions and identifying information gaps.
EUROPEAN JOURNAL OF CANCER
(2023)
Correction
Urology & Nephrology
Christina Guo, Ines Figueiredo, Bora Gurel, Antje Neeb, George Seed, Mateus Crespo, Suzanne Carreira, Jan Rekowski, Lorenzo Buroni, Jon Welti, Denisa Bogdan, Lewis Gallagher, Adam Sharp, Maria D. Fenor de la Maza, Pasquale Rescigno, Daniel Westaby, Khobe Chandran, Ruth Riisnaes, Ana Ferreira, Susana Miranda, Bianca Cali, Andrea Alimanti, Silvia Bressan, Alana H. T. Nguyen, Michael M. Shen, Jessica E. Hawley, Aleksandar Obradovic, Charles G. Drake, Claudia Bertan, Chloe Baker, Nina Tunariu, Wei Yuan, Johann S. de Bono
Article
Oncology
Susan Halabi, Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael A. Carducci, Kim N. Chi, Johann S. de Bono, Daniel P. Petrylak, Karim Fizazi, Celestia S. Higano, Michael J. Morris, Dana E. Rathkopf, Fred Saad, Charles J. Ryan, Eric J. Small, William Kevin Kelly
Summary: This study validated a prognostic model of overall survival in men with metastatic, castration-resistant prostate cancer treated with docetaxel. The model accurately predicts the survival of patients and performs well across different racial, age, and treatment subgroups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Valentine M. Macaulay, Simon Lord, Syed Hussain, Jose Pablo Maroto, Robert Hugh Jones, Miguel Angel Climent, Natalie Cook, Chia-Chi Lin, Shian-Shiang Wang, Diletta Bianchini, Mark Bailey, Laura Schlieker, Thomas Bogenrieder, Johann de Bono
Summary: This study evaluated the combination therapy of xentuzumab and enzalutamide in patients with metastatic castrate-resistant prostate cancer. The results showed that the combination treatment had some efficacy in certain patients.
BRITISH JOURNAL OF CANCER
(2023)
Article
Biochemical Research Methods
Rachel Lau, Lu Yu, Theodoros I. Roumeliotis, Adam Stewart, Lisa Pickard, Ruth Riisanes, Bora Gurel, Johann S. de Bono, Jyoti S. Choudhary, Udai Banerji
Summary: This study aimed to profile the proteome of cancer-associated fibroblasts (CAFs) and identify novel CAF biomarkers. The proteomic analysis revealed the upregulation of N-glycan biosynthesis and extracellular matrix proteins in CAFs, as well as the overexpression of heat shock protein & beta;-6 (HSPB6/HSP20) and cyclooxygenase 1 (PTGS1/COX1) as novel CAF biomarkers. Immunohistochemical analysis showed restricted expression of HSPB6 and PTGS1 in the stroma of tumor samples.
JOURNAL OF PROTEOMICS
(2023)
Article
Medicine, Research & Experimental
Antje Neeb, Ines Figueiredo, Bora Gurel, Daniel Nava Rodrigues, Jan Rekowski, Ruth Riisnaes, Ana Ferreira, Susana Miranda, Mateus Crespo, Daniel Westaby, Maria de Los Dolores Fenor de La Maza, Christina Guo, Juliet Carmichael, Rafael Grochot, Nina Tunariu, Andrew C. B. Cato, Stephen R. Plymate, Johann S. de Bono, Adam Sharp
Summary: BAG-1L protein plays a critical role in the development and progression of prostate cancer. This study developed a new BAG-1L-specific antibody and explored its expression in different types of prostate cancer and breast cancer tissues. The results showed higher BAG-1L protein expression in castration-resistant prostate cancer metastases, indicating a possible association with more aggressive biology and the development of castration resistance.
LABORATORY INVESTIGATION
(2023)
Article
Medicine, General & Internal
Christina Yap, Jan Rekowski, Moreno Ursino, Olga Solovyeva, Dhrusti Patel, Munyaradzi Dimairo, Christopher J. Weir, An-Wen Chan, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Richard Peck, Kathryn S. Hayward, Melanie Calvert, Khadija Rerhou Rantell, Shing Lee, Andrew Kightley, Sally Hopewell, Deborah Ashby, Elizabeth Garrett-Mayer, John Isaacs, Robert Golub, Olga Kholmanskikh, Dawn P. Richards, Oliver Boix, James Matcham, Lesley Seymour, S. Percy Ivy, Lynley Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Johann de Bono
Summary: SPIRIT 2013 provides guidance for clinical trial protocol writing but doesn't cover early phase dose-finding trials adequately. The DEFINE statement is a new guideline that includes recommendations for essential items in the protocols of these trials.
BMJ-BRITISH MEDICAL JOURNAL
(2023)
Article
Oncology
Daniela Brina, Adele Ponzoni, Martina Troiani, Bianca Cali, Emiliano Pasquini, Giuseppe Attanasio, Simone Mosole, Michela Mirenda, Mariantonietta D'Ambrosio, Manuel Colucci, Ilaria Guccini, Ajinkya Revandkar, Abdullah Alajati, Toma Tebaldi, Deborah Donzel, Fabio Lauria, Nahjme Parhizgari, Aurora Valdata, Martino Maddalena, Arianna Calcinotto, Marco Bolis, Andrea Rinaldi, Simon Barry, Jan Hendrik Rueschoff, Marianna Sabbadin, Semini Sumanasuriya, Mateus Crespo, Adam Sharp, Wei Yuan, Mathew Grinu, Alexandra Boyle, Cynthia Miller, Lloyd Trotman, Nicolas Delaleu, Matteo Fassan, Holger Moch, Gabriella Viero, Johann de Bono, Andrea Alimonti
Summary: In prostate cancer, the secretome is rewired at the translational level to recruit MDSCs, with Hgf, Spp1, and Bgn identified as key regulators. By inhibiting the MNK/eIF4E and AKT pathways, this study provides a therapeutic strategy that combines translation inhibition with immunotherapy to restore immune surveillance in prostate cancer.
Article
Oncology
Karim Fizazi, Ken Herrmann, Bernd J. Krause, Kambiz Rahbar, Kim N. Chi, Michael J. Morris, Oliver Sartor, Scott T. Tagawa, Ayse T. Kendi, Nicholas Vogelzang, Jeremie Calais, James Nagarajah, Xiao X. Wei, Vadim S. Koshkin, Jean-Mathieu Beauregard, Brian Chang, Ray Ghouse, Michelle DeSilvio, Richard A. Messmann, Johann de Bono
Summary: In the VISION study, lutetium-177 (177Lu) Lu-PSMA-617 improved radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. Additional results showed improvements in health-related quality of life, pain, and symptomatic skeletal events.
Article
Urology & Nephrology
Rafael Grochot, Suzanne Carreira, Susana Miranda, Ines Figueiredo, Claudia Bertan, Jan Rekowski, Wei Yuan, Ana Ferreira, Ruth Riisnaes, Antje Neeb, Bora Gurel, Maria de Los Dolores Fenor de la Maza, Christina Guo, Juliet Carmichael, Daniel Westaby, Joaquin Mateo, Adam Sharp, Terri P. McVeigh, Johann De Bono
Summary: This study investigated the clinical and pathological features of advanced prostate cancer associated with germline mutations in the ATM gene. It was found that most of these patients had a high family history of cancer, and this mutation may predict the progression of these prostate cancers and response to specific treatments.
Meeting Abstract
Oncology
Sumaira Sardar, Lakshmi Ravindranath, Christopher McNair, Saswati Chand, Wei Yuan, Denisa Bogdan, Jon Welti, Adam Sharp, Matthew Schiewer, Lisa Butler, Johann DeBono, Kris Frese, Nigel Brooks, Neil Pegg, Karen Knudsen